drugset / Trial / NCT00270296

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

NCT00270296

RandomizedParallel-groupDouble-blindPrevention

Summary

Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child transmission (MTCT) of HIV in developed countries. However, little is known of the effectiveness of such regimens in developing countries, such as Botswana. This study will determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana.

Timeline

Start
2006-06
Primary completion
2009-03
Completion
2010-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg Oral
Subject Lamivudine Other / unclassified 150 mg Oral
Subject Lopinavir Other / unclassified 400 mg Oral
Subject Nevirapine Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject Zidovudine Small molecule 300 mg Oral